Helen Wu - Concepedia

Author

Helen Wu

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

Helen Wu

Publications

220

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Royal Marsden Hospital University of Washington Macquarie University Centre Eugène Marquis

About

Helen Wu is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in cancer therapeutics, urology, and clinical trials.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	94
2	Health Sciences	3	3	79
3	Pharmacology	3	3	55
4	Diagnostic Sciences	2	2	55
5	Orthopaedics	2	2	31

Helen Wu

Publications

182

Citations

H-Index

Page 1

	Year	Citations
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial Chris Parker, Noel W. Clarke, Adrian Cook, The Lancet	2024	43
KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Evan Y. Yu, Josep M. Piulats, Gwénaëlle Gravis, Journal of Clinical Oncology UrologyPsa Response RateGenitourinary CancerClinical TherapeuticMedicine	2020	39
Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5. Julie N. Graff, Emmanuel S. Antonarakis, Christopher Hoimes, Journal of Clinical Oncology Bone DiseaseUrologyPsa Response RateEnza ResistanceMedicine	2020	24
Functional outcome after stroke in patients with rheumatoid arthritis and systemic lupus erythematosus Tracy U. Nguyen‐Oghalai, Helen Wu, Terry A. McNearney, Arthritis Care & Research	2008	23
KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). William L. Berry, Peter C.C. Fong, Josep M. Piulats, Journal of Clinical Oncology PharmacotherapyPre-clinical PharmacologyPsa Response RateOncologyGenitourinary Cancer	2020	16
KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). Michael Kolinsky, Gwénaëlle Gravis, Josep M. Piulats, Journal of Clinical Oncology Treatment-related AesPharmacotherapyPsoriatic ArthritisInflammatory ArthritisPre-clinical Pharmacology	2020	15
Neural patterns associated with mixed valence feelings differ in consistency and predictability throughout the brain Anthony G. Vaccaro, Helen Wu, Rishab Iyer, Cerebral Cortex	2024	12
Intestinal Pseudo-Obstruction Caused by Diltiazem in a Neutropenic Patient Rebecca P. Young, Helen Wu Annals of Pharmacotherapy	2005	10

Page 1